GSK PLC - London-based pharmaceuticals maker - Global Supply Chain President Regis Simard sells 38,000 shares at GBP20.38 each, for GBP774,440, on Wednesday in London. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The FTSE 100 made strong progress on Tuesday, buoyed by positive earnings and a drop in the oil price, which helped shrug off worries sparked by a chip sector sell-off in Asia. Read More
(Alliance News) - GSK PLC on Tuesday said it was planning a cost savings drive to fund investment in late-stage drug development as it reported second quarter results ahead of expectations. Read More
(Alliance News) - GSK PLC on Tuesday notes that licensor Hansoh Pharmaceutical Group Co Ltd has announced positive results from a "pivotal" phase 3 study of risvutatug rezetecan, or Ris-Rez. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has approved zidesamtinib, branded as Jideytro, for previously treated ROS1-positive non-small cell lung cancer. Read More
GSK PLC - London-based pharmaceutical maker - The European Medicines Agency accepts GSK's submission to update the label for Bexsero to include a single-dose booster for people aged 10 and older who previously had the vaccination against Meningitis B. "If adopted, a booster could help reduce the overall burden of invasive meningococcal disease in countries with established infant MenB programmes," GSK says. It says the submission is supported by a phase 3b, open-label, multi-centre study in 10- to 20-year-old patients, showing that a single dose was effective in boosting the immune responses of those vaccinated as infants. Invasive meningococcal disease is a rare disease caused by Neisseria meningitidis that can progress rapidly and has a fatality rate of 4% to 20%, GSK notes. Read More
(Alliance News) - The FTSE 100 was called to open lower on Monday, after the US and Iran exchanged further strikes and as Andy Burnham prepares to officially succeed Keir Starmer as prime minister. Read More
(Alliance News) - Stock prices in London were lower at midday on Friday as investors assessed fresh eurozone inflation data and escalating tensions in the Middle East. Read More
(Alliance News) - GSK PLC on Friday said it will not progress its development of camlipixant for refractory chronic cough, after phase 3 study data suggested that it "is unlikely to transform patient care". Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
GSK PLC - London-based pharmaceutical company - Completes takeover of Nuvalent Inc, a Boston, Massachusetts-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. The total value of the acquisition is about USD10.6 billion. Net of cash acquired, GSK's total investment is about USD9.4 billion. The transaction adds three lung cancer assets to GSK's oncology portfolio, with zidesamtinib and neladalkib "considered potential best-in-class assets", and under Food & Drug Administration review for ROS1-positive and ALK-altered non-small cell lung cancer. GSK says: "Both have received FDA breakthrough therapy and orphan drug designations. If approved, they are expected to launch in 2026 with multi-blockbuster potential." Read More
(Alliance News) - GSK PLC on Monday reported encouraging trial data for its cancer treatment Jemperli, also known as dostarlimab. Read More
(Alliance News) - Stock prices in London opened slightly lower on Monday as renewed tensions between the US and Iran lifted oil prices. Read More
(Alliance News) - GSK reports positive Jemperli trial data, while Plus500 posts record first-half revenue. Elsewhere, Heathrow's first-half passenger traffic edged higher despite a June decline caused by weaker Middle East travel. Read More
(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or relapsed small-cell lung cancer. Read More
(Alliance News) - GSK PLC on Thursday announced that Roy Jakobs, the chief executive officer of Royal Philips NV, will join its board next week as a non-executive director. Read More